Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
12/16/2011
Trade Name:
Maxalt and Maxalt-MLT
Generic or Proper Name (*):
rizatriptan
Indications Studied:
Treatment of migraine
Therapeutic Category:
Antimigraine
Ages Studied:
12-17 years
Study #:
3
Study Type:
Safety
Study Design:
Open Label
No Patients:
373
No Centers:
146
No Countries:
4
BPCA(B), PREA(P):
B
Asian:
1
Black:
38
Other:
11
White:
320
Unknown:
0
American Indian/Alaska Native:
3
Hispanic/Latino:
39
Non-Hispanic/Non Latino:
334
Countries:
US, Finland, Sweden, the Netherlands
-
-